Toward a working definition of C3 glomerulopathy by immunofluorescence

Kidney International

Volumn 85, Issue 2, 2014, Pages 450-456

  Hou, Jean ^a   Markowitz, Glen S ^a   Bomback, Andrew S ^b   Appel, Gerald B ^b   Herlitz, Leal C ^a   Barry Stokes, M ^a   D'agati, Vivette D ^a  

^a Howard Hughes Medical Institute   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3C; FIBRIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M;

ADULT; ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GLOMERULOPATHY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; INCIDENCE; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE 1; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE 2; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE 3; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; BIOPSY; COMPLEMENT C1Q; COMPLEMENT C3; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KIDNEY GLOMERULUS; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TERMINOLOGY AS TOPIC;

EID: 84895905249     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.340     Document Type: Article

References (27)

1. Mandalenakis N, Mendoza N, Pirani CL et al. Lobular glomerulonephritis and membranoproliferative glomerulonephritis: A clinical and pathologic study based on renal biopsies. Medicine 1971; 50: 319-355
2. Levy M, Gubler MC, Sich M et al. Immunopathology of membranoroliferative glomerulonephritis with subendothelial deposits (Type I MPGN). Clin Immunol Immunopathol 1978; 10: 477-492
3. Habib R, Gubler MC, Loirat C et al. Dense deposit disease: A variant of membranoproliferative glomerulonephritis. Kidney Int 1975; 7: 204-215
4. Strife CF, McEnery PT, McAdams AJ et al. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin Nephrol 1977; 7: 65-72
5. Burkholder PM, Hyman LR, Krueger RP. Characterization of mixed membranous and proliferative glomerulonephritis: Recognition of three varieties. Perspect Nephrol Hypertens 1973; 1(Pt 1): 557-589
6. Walker PD, Ferrario F, Joh K et al. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 2007; 20: 605-616
7. Sethi S, Fervenza FC, Zhang Y et al. C3 glomerulonephritis: Clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82: 465-473
8. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: Pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31: 341-348
9. Fakhouri F, Fremeaux-Bacchi V, Noel LH et al. C3 glomerulopathy: A new classification. Nat Rev Nephrol 2010; 6: 494-499
10. Habbig S, Mihatsch MJ, Heinen S et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75: 1230-1234
11. Abrera-Abeleda MA, Nishimura C, Frees K et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011; 22: 1551-1559
12. Strobel S, Zimmering M, Papp K et al. Anti-factor B autoantibody in dense deposit disease. Mol Immunol 2010; 47: 1476-1483
13. Goodship TH, Pappworth IY, Toth T et al. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol 2012; 52: 200-206
14. Ohi H, Watanabe S, Fujita T et al. Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN). Clin Exp Immunol 1992; 89: 479-484
15. Sethi S, Gamez JD, Vrana JA et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75: 952-960
16. Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657
17. Bolton WK, Benton FR, Maclay JG et al. Spontaneous glomerular sclerosis in aging Sprague-Dawley rats. I. Lesions associated with mesangial IgM deposits. Am J Pathol 1976; 85: 277-302
18. Servais A, Noel LH, Roumenina LT et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454-464
19. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012; 8: 634-642
20. Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens 2013; 22: 231-237
21. He RJ, Xiao HJ, Wang SX et al. [Characteristics of pediatric C3 glomerulopathy with decreased factor H in 3 cases]. Zhonghua Er Ke Za Zhi 2012; 50: 939-943
22. Athanasiou Y, Voskarides K, Gale DP et al. Familial C3 glomerulopathy associated with CFHR5 mutations: Clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6: 1436-1446
23. Gale DP, de Jorge EG, Cook HT et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376: 794-801
24. D'Agati VD, Bomback AS. C3 glomerulopathy: What's in a name? Kidney Int 2012; 82: 379-381
25. Sandhu G, Bansal A, Ranade A et al. C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. Am J Kidney Dis 2012; 60: 1039-1043
26. Zand L, Kattah A, Fervenza FC et al. C3 glomerulonephritis associated with monoclonal gammopathy: A case series. Am J Kidney Dis 2013; 62: 506-514
27. Herlitz LC, Bomback AS, Markowitz GS et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23: 1229-1237